CRTX CRTX

Cortexyme Share Price - CRTX

14.50
1.49 (11.45%)
14.50
Volume 2,841,626
Bid Price 14.50
Ask Price 14.58
News -
Day High 14.20

Low
11.54

52 Week Range

High
121.98

Day Low 12.82
Best deals to access real time data!
USA Big Cap Pro
Monthly Subscription
for only
US$52.04
North American Extreme
Monthly Subscription
for only
US$104.50
USA Level 1 Starter
Monthly Subscription
for only
US$15.87
VAT not included
Stock Name Stock Symbol Market Stock Type
Cortexyme Inc CRTX NASDAQ Common Stock
  Price Change Price Change % Stock Price Last Trade
1.49 11.45% 14.50 18:47:52
Open Price Low Price High Price Close Price Previous Close
13.03 12.82 14.20 13.91 13.01
Trades Stocks Traded VWAP Financial Volume Average Volume 52 Week Range
22,203 2,841,626 US$ 13.61 US$ 38,672,268 - 11.54 - 121.98
Last Trade Type Quantity Price Currency
18:46:56 formt 535 US$ 14.50 USD

Period:

Draw Mode:

Cortexyme Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 433.23M 29.88M 17.29M US$ - US$ - -2.63 -4.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- US$ - - -43.96k 2.60%

more financials information »

Cortexyme News

Date Time Source News Article
11/23/202107:00Business WireCortexyme to Present at 4th Annual Evercore ISI HealthCONx..
11/12/202117:47Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
11/11/202110:52Seeking AlphaCortexyme posts more data from Alzheimer’s trial to show..
11/11/202110:30Business WireCortexyme’s Atuzaginstat Slowed Cognitive Decline in..
11/04/202107:00Business WireCortexyme to Present Additional Top-line GAIN Trial Results..
10/29/202108:03Edgar (US Regulatory)Quarterly Report (10-q)
10/26/202115:12Edgar (US Regulatory)Current Report Filing (8-k)
10/26/202115:01Business WireCortexyme Reports GAIN Trial Data Demonstrated Relationship..
10/15/202121:04Seeking AlphaJasper more than doubles while M&A headlines weekly..
10/08/202111:04Edgar (US Regulatory)Schedule 13g
10/07/202117:24Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)
9/27/202107:00Business WireCortexyme to Present Results from the GAIN Trial: A Phase..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week12.0914.2011.5412.571,236,5612.4119.93%
1 Month16.330617.9811.5414.732,119,468-1.83-11.21%
3 Months90.0098.5011.5420.801,964,958-75.50-83.89%
6 Months41.64121.9811.5428.541,052,498-27.14-65.18%
1 Year49.68121.9811.5430.03670,142-35.18-70.81%
3 Years20.00121.9811.5433.07332,423-5.50-27.5%
5 Years20.00121.9811.5433.07332,423-5.50-27.5%

Cortexyme Description

Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics.
Your Recent History
NASDAQ
CRTX
Cortexyme
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211202 01:02:53